Form 4: Vertex Pharmaceuticals Executive Ourania Tatsis Reports Stock Transactions

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports the acquisition and disposal of company stock.

Summary

• On February 23, 2024, Ourania Tatsis acquired 3,309 shares of Vertex Pharmaceuticals common stock at a price of $431.79.
• These shares were acquired through a transaction coded 'F', which typically indicates the satisfaction of a tax liability by surrendering shares.
• On February 26, 2024, Ms. Tatsis disposed of 354 shares of common stock at a price of $425.7.
• The transaction was a sale, indicated by the code 'S'.
• Following these transactions, Ms. Tatsis directly owns 55,804 shares of Vertex Pharmaceuticals common stock.
• The initial transaction was made pursuant to a pre-arranged trading plan under Rule 10b5-1, established on May 9, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of company leadership.

Key Dates